• Oncolytics Biotech won FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.
• Designation covers inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal following prior systemic therapy.
• GOBLET study data cited an objective response rate near 30% with a median duration of response about 15.5 months.
• Oncolytics pegged the U.S. opportunity at about USD 1 billion a year, citing no FDA-approved options post first-line standard of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200900PRIMZONEFULLFEED9764534) on July 20, 2026, and is solely responsible for the information contained therein.